These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Therapeutic use of prostacyclin in cardiovascular pathology]. Martelli M; Nicolosi G Minerva Med; 1983 Nov; 74(44):2665-70. PubMed ID: 6419178 [TBL] [Abstract][Full Text] [Related]
7. Possibilities for clinical use of prostacyclin in vascular disease. Poredos P Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643 [TBL] [Abstract][Full Text] [Related]
9. Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. Kerins DM; Murray R; FitzGerald GA Prog Hemost Thromb; 1991; 10():307-37. PubMed ID: 1848945 [No Abstract] [Full Text] [Related]
10. [Drug therapy of vasculitis with prostaglandins]. Makino S Nihon Rinsho; 1985 Oct; 43(10):2200-5. PubMed ID: 3912548 [No Abstract] [Full Text] [Related]
11. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD). Fitscha P; Tiso B; Krais T; Sinzinger H Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079 [No Abstract] [Full Text] [Related]
12. Treprostinil (Remodulin) for pulmonary arterial hypertension. Med Lett Drugs Ther; 2002 Sep; 44(1139):80-2. PubMed ID: 12237619 [No Abstract] [Full Text] [Related]
13. [Prostaglandins and arteriosclerosis. Action of PGI 2 (PGX) on platelet aggregation]. Messini M; Messini F Clin Ter; 1979 Jul; 90(1):3-9. PubMed ID: 394908 [No Abstract] [Full Text] [Related]
14. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans. Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655 [No Abstract] [Full Text] [Related]
15. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease. Darius H; Kopp H; Mulfinger A; Spielberger M; Todt M; Schuster CJ; Meyer J Prog Clin Biol Res; 1989; 301():417-21. PubMed ID: 2508112 [No Abstract] [Full Text] [Related]
16. [Use of a new sympatholytic drug in therapy of chronic peripheral obliterating artery diseases]. Vittori C; Taborelli G; Taborelli R Minerva Cardioangiol; 1965 Sep; 13(9):585-91. PubMed ID: 5851172 [No Abstract] [Full Text] [Related]
17. [Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation]. Fabiani JN; Bunting S; Terrier E; O'Grady J; Fontaine B; Prigent C; Carpentier A; Vane J; Dubost C Arch Mal Coeur Vaiss; 1982 Mar; 75(3):241-8. PubMed ID: 6807240 [TBL] [Abstract][Full Text] [Related]
18. [Effect of surheme on improved blood flow in limbs]. Wesolowski J; Hubl S; Godziemba-Maliszewska E Wiad Lek; 1972 Jul; 25(14):1297-300. PubMed ID: 5054661 [No Abstract] [Full Text] [Related]
19. Dipyridamole and aspirin in arteriosclerosis obliterans of the lower limbs. Davì G; Pinto A; Palumbo MG; Gallo V; Mazza A; Strano A Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():271-5. PubMed ID: 3159212 [No Abstract] [Full Text] [Related]
20. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. Davì G; Pinto A; Francavilla G; Paterna S; Campisi D; Strano A Thromb Res; 1985 Oct; 40(2):275-81. PubMed ID: 2933846 [No Abstract] [Full Text] [Related] [Next] [New Search]